SCHEMBL28203631

SCHEMBL28203631

O=C[CH]c1cccc(Cl)c1C(=O)Nc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 5/20 0.53
▸ JAK2 O60674 3/20 0.53
▸ JAK1 P23458 3/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ NPC1 O15118 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ MAOB P27338 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ TAS1R3 Q7RTX0 1/20 0.49
▸ TAS1R1 Q7RTX1 1/20 0.49
▸ TAS1R2 Q8TE23 1/20 0.49
▸ PTGS2 P35354 1/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ ITGB1 P05556 2/20 0.46
▸ ITGA4 P13612 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ EGFR P00533 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28448935 0.88 TYK2 (0.55) TYK2JAK2JAK1CYP3A4NPC1
SCHEMBL4154853 0.84 TYK2 (0.71) TYK2JAK2JAK1CYP3A4MAPT
SCHEMBL30230787 0.80 TYK2 (0.75) TYK2JAK2JAK1CYP3A4TAS1R3
SCHEMBL9884060 0.80 TYK2 (0.75) TYK2JAK2JAK1CYP3A4TAS1R3
SCHEMBL3791414 0.78 SMO (0.61) TYK2JAK2JAK1CYP3A4NPC1
SCHEMBL2168022 0.78 TYK2 (0.58) TYK2JAK2JAK1CYP3A4MAPT
SCHEMBL14991989 0.76 JAK1 (0.75) TYK2JAK2JAK1CYP3A4MAPT
SCHEMBL2845491 0.76 F2R (0.63) TYK2JAK2JAK1CYP3A4NPC1
SCHEMBL29493359 0.74 JAK2 (0.54) TYK2JAK2JAK1CYP3A4NPC1
SCHEMBL6602761 0.73 TYK2 (0.61) TYK2JAK2JAK1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107690433-A Heteroaryl derivative or its pharmaceutically acceptable salt, its preparation method and include the pharmaceutical composition for being used to prevent or treat PI3 kinase-associated conditions ited as active component 韩国化学研究院 2018-02-13 — — CN disclosed
Send feedback